Ginkgo Bioworks Holdings, Inc. (DNA)
Stock analysis · NYSE · Healthcare · Biotechnology
Ginkgo Bioworks Holdings, Inc. (DNA) is a publicly traded company in the Healthcare sector. Latest price: $13.32. Market cap $896.97M. Trailing PE -2.65. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Earnings
Proprietary Signals
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and governmen…
Valuation
| P/E (TTM) | -2.65× |
|---|---|
| P/S (TTM) | 8.02× |
| P/B | 1.97× |
| P/FCF (TTM) | -4.72× |
| EV / EBITDA | -5.03× |
| EV / Sales | 10.88× |
| Earnings Yield | -35.16% |
| Free Cash Flow Yield | -21.20% |
Fundamentals
| Enterprise Value | $1.22B |
|---|---|
| Revenue (TTM) | $111.86M |
| Net Income (TTM) | -$315.37M |
| Free Cash Flow (TTM) | -$190.12M |
| Net Debt | $319.58M |
| Working Capital | $259.80M |
| Gross Margin | 80.09% |
| Operating Margin | -259.86% |
| Net Margin | -259.96% |
| Return on Equity | -60.21% |
| Return on Invested Capital | -31.63% |
Peers
Recent News
- Hugging Face is launching a new AI model that lets scientists 'chat with DNA'
- Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational…
- Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
- Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
- What's Going on With Ginkgo Bioworks Stock on Friday?
Related
Browse more tickers: sitemap